Drug Profile
RPI 78M
Alternative Names: Alpha-cobratoxin-derived peptide; Alpha-Immunokine; Receptin; RPI-78MLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Bio Therapeutics
- Developer ReceptoPharm
- Class Antivirals; Immunotherapies; Peptides
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Adrenomyeloneuropathy
- No development reported Herpes simplex virus infections; Herpes zoster; Multiple sclerosis
- Discontinued Rabies
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Adrenomyeloneuropathy in USA (Buccal, Spray)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (SC, Injection)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (Topical, Cream)